Goldman Sachs’s SpringWorks Therapeutics SWTX Stock Holding History

Goldman Sachs’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200,000	Closed	-$9.4M	–	6643
2025 Q2	$9.4M	Buy	200,000 +170,200	+571%	+$7.57M	﹤0.01%	2817
2025 Q1	$1.32M	Buy	+29,800	New	+$1.37M	﹤0.01%	4486

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's SWTX Position: Q3 2025 in Review

Goldman Sachs sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 2,275,449 shares — an estimated $107M sold.

Goldman Sachs first reported a position in SWTX in Q3 2019 and held it in 22 quarters. The position peaked at $107M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Goldman Sachs reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Goldman Sachs sold 2,275,449 SpringWorks Therapeutics shares in Q3 2025, an estimated $107M.
Goldman Sachs first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 22 quarters.
Goldman Sachs's SpringWorks Therapeutics position peaked at $107M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.